• To be able to use molecular imaging adequately in daily practice

  • Awareness of different molecular imaging techniques and tracers

  • Appreciation of geographical variation in the availability of different molecular imaging techniques and tracers

  • Recognition of upcoming molecular imaging techniques that are potentially of benefit for the patient

  • Awareness of the existence of hybrid imaging systems

  • Appreciation of radionuclide therapies

  • Recognition of potentially relevant novel tracers such as 68Ga-DOTATOC, 3,4-dihydroxy-6-(18)F-fluoro-l-phenylalanine [18F-FDOPA], 18F-fluoroestradiol [18F-FES], 11C or 18F-choline and 11C-methionine

  • Understanding of the complementary role of molecular and anatomic imaging

  • Familiarity with the indications for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) scans for the different tumour types as defined in guidelines

  • Familiarity with the patient preparation before the different scans

  • Familiarity with the principles of SPECT and PET imaging

  • Understanding of the behaviour and biodistribution of standard molecular imaging tracers (technetium-99m [99mTc]-labelled diphosphonates scan, 18F-fluorodeoxyglucose [18F-FDG]-PET, Indium-111 [111In]-octreotide scan, 123I-metaiodobenzylguanidine [123I-MIBG] scan and 123I/131I-iodine scans)

  • Familiarity with the guidelines for the relevance of 99mTc-labelled diphosphonates scan, 18F-FDG-PET, 111In-octreotide scan, 123I-MIBG scan and 123I/131I-iodine scans

  • Familiarity with the role of 18F-FDG-PET in Response Evaluation Criteria in Solid Tumours (RECIST) 1.1

  • Familiarity with the role of 18F-FDG-PET in lymphoma staging and response measurement

  • Familiarity with the indications and interpretation of a multigated acquisition (MUGA) scan with 99mTc-pertechnetate

  • Understanding of how information derived from imaging influences treatment decision-making

  • Familiarity with the radiation doses administered with molecular imaging techniques

  • Familiarity with existing radionuclide therapies

  • Ability to interpret a physiological biodistribution, pathological uptake and pitfalls and artefacts of molecular imaging techniques

  • Ability to contribute to the presentation of molecular imaging findings of patient cases

  • Ability to apply RECIST 1.1

  • Ability to use imaging information for patient care

  • Ability to select the right indications for molecular imaging for staging and response measurements

  • Ability to interpret left ventricular ejection fraction

  • Ability to take care of patients who receive radionuclide therapy